FEATURE ARTICLES
Though I still have a great deal to learn about the pharmaceutical industry, I am surrounded by a warm and incredibly bright cast of editors that I gain knowledge from every day.
- Top 7 AI Lessons Learned
- An AI Use Case in Pharma Process Optimization
- Reimagining HACCP And Other Process Flow Risk Analysis Methods Using Relational Risk Analysis
- November 2025 — CDMO Opportunities And Threats Report
- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- Unpacking The EU's Mutual Recognition Agreements For Pharma
- It's Copy/Paste In Fleet Management Manufacturing
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-2148124393 DNA]( "A Risk-Based Approach To Plasmid DNA And mRNA Process Development")
A Risk-Based Approach To Plasmid DNA And mRNA Process DevelopmentBalancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Meet Regulation Requirements With RTU Vials And Cartridges10/9/2025
Sterile manufacturing remains vital, with resilient supply chains preventing shortages. Industry and regulators prioritize integrity as demand surges, making it the fastest-growing pharmaceutical segment.
-
Isolators For Pharmacy Compounding – Time For Change?3/14/2025
Maintaining a contamination-free environment is crucial in drug compounding. Learn how isolator systems can improve safety, efficiency, and regulatory compliance.
-
SMB Technology: Optimizing API Purification6/13/2025
Explore how Simulated Moving Bed (SMB) technology can enhance API production while overcoming common misconceptions about chromatographic purification.
-
Generate CHO-K1 GFP-Expressing Cells For Cell Line Development Workflow11/7/2025
Discover a high-efficiency workflow for generating GFP-expressing CHO-K1 clones using automated single-cell dispensing to achieve 93% isolation success and stable expression in under five weeks.
-
The Complete Flow Cytometry Guide9/24/2024
This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Navigating Regulatory Compliance: A Success Story In The Pharma Industry
- Seamlessly Integrating An E-WorkBook With A Customer's LIMS
- Cytokine-Mediated Inflammation In A Relevant Preclinical Model
- Low Adsorption UPLC Systems And Columns
- Achieving Faster Timelines And Cost Savings Through Digital Validation
NEWSLETTER ARCHIVE
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
INTERPHEX Opens Registration For 2026 With Expanded Show Floor, Education And Debut Of New Contract & Outsourcing Hub1/14/2026
INTERPHEX, the premier pharmaceutical and biotechnology event returns to NYC, taking place April 21 – 23 at the Javits Center. Representing the full scope of the pharmaceutical value chain, INTERPHEX continues to be the event to discover breakthrough solutions that enhance manufacturing, development, regulatory compliance and supply chain efficiency to support the evolving industry.
-
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services1/14/2026
The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.
-
Johnson & Johnson Announces Plans For New Manufacturing Facilities In North Carolina And Pennsylvania1/13/2026
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs.
-
Sharp Sterile Manufacturing Increases Capacity With $28 Million Investment Featuring New IMA Isolated Vial Filling Line1/8/2026
Sharp Sterile Manufacturing has today announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will strengthen opportunities for highly skilled engineering and pharmaceutical manufacturing roles within the local life sciences community and represents a major milestone in Sharp Sterile’s development.
-
CDMO GBI Biomanufacturing Announces New President1/6/2026
GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.
